You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 64 No. 9, September 2007 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 •Notice of Failure to Disclose Financial Interest
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (38)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Alzheimer Disease
 •Cognitive Disorders
 •Randomized Controlled Trial
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials

John Harrison, C. Psychol, PhD; Sonia L. Minassian, DrPH; Lisa Jenkins, PhD; Ronald S. Black, MD; Martin Koller, MD, MPH; Michael Grundman, MD, MPH

Arch Neurol. 2007;64(9):1323-1329.

Objective  To report the psychometric properties of an alternative instrument to the cognitive subscale of the Alzheimer's Disease Assessment Scale, a neuropsychological test battery (NTB) for measuring drug efficacy in Alzheimer disease clinical trials.

Design  The NTB was evaluated in a randomized, double-blind, placebo-controlled trial of AN1792(QS-21) (synthetic β-amyloid plus an adjuvant) (300 patients) and isotonic sodium chloride solution (72 patients). The test-retest reliability of the NTB was examined, and the NTB was correlated with other cognitive (cognitive subscale of the Alzheimer's Disease Assessment Scale and Mini-Mental State Examination) and functional (Disability Assessment Scale for Dementia and Clinical Dementia Rating Sum of Boxes) measures. In addition, a factor analysis was performed on NTB components. Finally, the sensitivity of the NTB to change was assessed as a function of Mini-Mental State Examination performance.

Results  The NTB had high test-retest reliability at 6 (Pearson product moment correlation [r] = 0.92) and 12 (r = 0.88) months. Internal consistency was high (Cronbach {alpha} = 0.84). The correlations between the NTB z score and scores on traditional measures of cognition and function were significantly different from 0 (P < .001). A factor analysis yielded "memory" and "executive function" factors. The NTB z score declined linearly over 1 year in patients receiving placebo and, in contrast to the Alzheimer's Disease Assessment Scale cognitive subscale, demonstrated similar declines in patients with high (21-26) and low (15-20) Mini-Mental State Examination scores at baseline.

Conclusions  The NTB exhibits excellent psychometric properties and seems to be a reliable and sensitive measure of cognitive change in patients with mild to moderate Alzheimer disease. The psychometric properties of the NTB suggest that it may have particular utility in evaluating drug efficacy in clinical trials in which patients with mild Alzheimer disease are included.


Author Affiliations: CPC Pharma Services, Warminster, England (Dr Harrison); Elan Pharmaceuticals, San Diego, California (Drs Minassian, Koller, and Grundman); and Wyeth Research, Collegeville, Pennsylvania (Drs Jenkins and Black).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

Notice of Failure to Disclose Financial Interest: "A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials" (Arch Neurol. 2007;64[9]:1323-1329)
John Harrison
Arch Neurol. 2008;65(7):992.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway et al.
Neurology 2011;77:1253-1262.
ABSTRACT | FULL TEXT  

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway et al.
Neurology 2009;73:2061-2070.
ABSTRACT | FULL TEXT  

Toward Establishing Guidelines for Evaluating Cognitive Enhancement With Complementary and Alterative Medicines
Solomon and Michalczuk
Eval Health Prof 2009;32:370-392.
ABSTRACT  

Notice of Failure to Disclose Financial Interest: "A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials" (Arch Neurol. 2007;64[9]:1323-1329)
Harrison
Arch Neurol 2008;65:992-992.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.